Rivaroxaban and dabigatran etexilate have low molecular weights. They have specific and restricted anticoagulant activities (Fig. 1) . Although their mechanisms of action are different, the specificity of activity has no known clinical relevance and both drugs are effective anticoagulants.
antagonist of thrombin. Thrombin is a multifunctional enzyme which converts fibrinogen to fibrin, cross-linking fibrin monomers via activation of factor XIII and augmenting further thrombin production via the activation of factors V and VIII.
It also activates platelets, generates anticoagulant activity via activation of protein C and initiates numerous cellular processes including wound healing. Most of the actions of thrombin are inhibited in vitro by dabigatran etexilate.
pharmacokinetics
The essential properties of the new anticoagulants are compared to warfarin in Table 1 . Their main advantages are a rapid onset of anticoagulant effect, more predictable pharmacokinetics, and a lower potential for clinically important interactions with food, lifestyle and other drugs. There is no requirement for routine monitoring and dose adjustment as required with warfarin.
Rivaroxaban
Rivaroxaban 1 10 mg tablets are well absorbed (80% bioavailability) with no effect of food on absorption or pharmacokinetic parameters. Plasma concentrations peak at 2.5-4 hours. The plasma elimination half-life is 5-9 hours in young adults and 11-13 hours in older people due to the agerelated decline in renal function. This permits once-or twicedaily dosing.
Rivaroxaban is metabolised by liver enzymes, principally cytochrome P450 3A4, and also by cytochrome-independent mechanisms. There are no known active metabolites.
Rivaroxaban has a dual mechanism of excretion. Approximately 66% of the dose is excreted via the kidneys, in roughly equal proportions of rivaroxaban and inactive metabolites. The remainder is excreted by the faecal-biliary route. Intestinal excretion of rivaroxaban appears to be mediated, at least in part, by P-glycoprotein, a transport protein, because potent P-glycoprotein inhibitors will increase plasma concentrations of rivaroxaban.
Dabigatran
Dabigatran is a hydrophilic polarised membrane-impermeable molecule which is not absorbed after oral dosing. The oral formulation, dabigatran etexilate, 2 is a prodrug with low bioavailability (approximately 6.5%) and its absorption in The absorption of dabigatran etexilate is reduced by 20-25% if patients are also given proton pump inhibitors. 
Self-test questions
The following statements are either true or false The program is also available free to pharmacists, nurse practitioners and other health professionals.
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